Specialty

Respiratory: ‘Real world evidence’ is a bit of a buzz word in research circles at the moment. Increasingly this type of evidence is being used to inform both regulatory and payor decision-making. But what does it mean clinically? And should we be paying attention? In this interview we discuss real world evidence, with a particular focus on severe asthma biologics.
23-minute listen

The Australian Mepolizumab Registry is an investigator-initiated and managed study funded through the GlaxoSmithKline Investigator-Sponsored Studies program

Respiratory: Up until now, the treatment for severe asthma with biologic medications has been predominantly administered by healthcare practitioners. In this interview, we’ll explore the paradigm shift towards patients self-administering biologic treatments. How do we choose patients who are suitable for self-administration? How might empowering patients to self-administer treatment reduce current barriers faced by patients and improve convenience?
15-minute listen

Epilepsy: Epilepsy is commonly diagnosed in adolescence, affecting approximately 1% of children aged 14 to 16 years. At a time of critical intellectual, physical, hormonal and social development, epilepsy can have a significant effect on the teenager’s lifestyle. Choosing the right anti-epileptic drug from the start can have significant benefits to teenagers, enabling them to gain the necessary independence and self-empowerment to mature through adolescence.
23-minute listen

Epilepsy: What are the most significant understandings in genetics that have happened over the last few years, and what have been the big breakthroughs? In this interview we present a remarkable view of this incredibly wide ranging field, where there have been so many dramatic developments. We provide a valuable background and some practical advice about what we can say to patients, and how to approach screening issues.
30-minute listen

Dentist: This update for Dentists, explains the latest evidence and recommendations for minimising the risk for ONJ and maintaining fracture protection in patients being treated for osteoporosis.

Psychiatry: In this interview we discuss major depressive disorder (MDD) in all its complexity and the challenge it presents to us. MDD not only impacts a patient’s mood, but also their social lives, their professional lives and of course their family and other relationships. We discuss these issues in the setting of treatment choices and the importance of identifying and treating the constellation of MDD symptoms in practice.

Psychiatry: We will often identify psychotic symptoms and be responsible for considering antipsychotic therapy in patients who are treatment naïve. In this interview we look at the considerations that are important when we are contemplating treatment choice.

Psychiatry: Conventionally during the acute phase of psychosis, we’ve tended to focus on short-term treatment of intense positive symptoms, hostility and agitation, and may not consider long-term treatment goals such as the improvement of negative symptoms and cognitive deficits the way we might like. In this interview, we’re talking about the importance of considering long-term treatment goals of schizophrenia when treating patients with psychosis in the acute phase.

NEW Psychiatry. Schizophrenia is a treatable condition, we have good treatments and treatment does lead to remission if we deliver the appropriate treatment. In this interview we discuss the biggest challenges that we face as a clinicians, particularly in patients with an established diagnosis of schizophrenia, as well as patient priorities and how we can balance trust in the relationship while making sure that they have the best outcome.

Psychiatry. Schizophrenia is a cyclical disease with approximately 94% of patients experiencing multiple episodes of psychosis. During periods of acute psychosis, patients may require hospitalisation, however eventually they will be discharged, and it’s during this period that transition care arrangements are very important. In this interview we discuss managing patients as they move from inpatient hospitalisation, back to community care.